Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
23andMe
MedTech
23andMe shutters cancer drug research, lays off 40% of staff
The genetics testing company plans to seek out new homes for its in-house pipeline of DNA-informed immuno-oncology antibodies.
Conor Hale
Nov 11, 2024 9:07pm
23andMine: Anne Wojcicki aims to take genetics company private
Apr 18, 2024 9:16am
23andMe lands new label for cholesterol drug response report
Oct 27, 2022 11:12am
23andMe snags 3rd FDA nod for genetic cancer risk test
Jan 10, 2022 11:58am
23andMe to go public in $3.5B deal backed by Virgin
Feb 4, 2021 11:25am
23andMe to lay off 100 as sales turn: CNBC
Jan 24, 2020 10:41am
